Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01541644 · ClinicalTrials.gov registry record · NA

1068GCC Evaluate Efficacy & Explore Mechanism of Acupuncture in Treating Bortezomib-induced Peripheral Neuropathy (BIPN) in Multiple Myeloma

A NA study of Multiple Myeloma and Peripheral Neuropathies, sponsored by University of Maryland, Baltimore.

Completed
Registry status
NA
Development phase
27
Enrollment target
1
Study location

NCT01541644: Completed NA study of Multiple Myeloma and Peripheral Neuropathies, sponsored by University of Maryland, Baltimore.

NCT01541644 is a NA study of Multiple Myeloma and Peripheral Neuropathies that has completed, run by University of Maryland, Baltimore. The registered enrollment target is 27 participants, below the 547-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01541644, a NA study of Multiple Myeloma and Peripheral Neuropathies, has completed, sponsored by University of Maryland, Baltimore.

COMPLETED
Registry status
NA
Development phase
27 participants
Enrollment target
1
Study location

Study Summary

Patients are asked to be in this study if they have multiple myeloma and are having tingling, numbness and pain from taking bortezomib (velcade®). Patients who have been diagnosed with multiple myeloma often take bortezomib (velcade®). This research is being done to find out if acupuncture can reduce the nerve pain, tingling, and/or numbness patients experience due to bortezomib (velcade®). Acupuncture is a medical technique of inserting very thin needles into the "energy points" on the body with the aim to restore health and well-being. It has been used widely to treat pain, such as lower back pain and nerve pain. In this study we will see if acupuncture can be used to ease nerve pain and tingling, numbness that is caused by bortezomib.

Primary Outcome

The Neuropathic Pain Scale (NPS) uses self-report visual analogue scales (VAS) to quantify on a scale of 0-10 (with total NPS score of 1-100), global pain intensity and unpleasantness and 8 other descriptive qualities of neuropathic pain. Response defined as average change of Clinical Total Neuropathy Score (TNSc) greater than or equal to 10% over 10 weeks compared to baseline. Effect defined as as average change of Functional Assessment of Cancer Therapy-Neurotoxicity/ Gynecologic Oncology Grou

Interventions

  • DEVICE Acupuncture

Study Locations (1)

Maryland

  • University of Maryland Marlene & Stewart Greenebaum Cancer Center - Baltimore

Trial Details

FieldValue
Enrollment Target 27 participants
Start Date 2011-05
Est. Completion 2014-12
Phase NA
University of Maryland, Baltimore

560 total trials

What the finished NCT01541644 record still lists

NCT01541644 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 27 participants, a relatively small participant target, below the 547-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (95% lower).

The record links to 2 conditions, with Multiple Myeloma appearing as the primary indexed condition, and to 1 intervention - of which Acupuncture is the first listed.

NCT01541644 reports a single indexed study location in Maryland.

Frequently Asked Questions

What is clinical trial NCT01541644 about?

NCT01541644 is a clinical study titled "1068GCC Evaluate Efficacy & Explore Mechanism of Acupuncture in Treating Bortezomib-induced Peripheral Neuropathy (BIPN) in Multiple Myeloma". Patients are asked to be in this study if they have multiple myeloma and are having tingling, numbness and pain from taking bortezomib (velcade®). Patients who have been diagnosed with multiple myeloma often take bortezomib (velcade®). This research is being done to find out if acupuncture can redu...

What is the current status of trial NCT01541644?

This trial is currently completed. It is a NA study. The enrollment target is 27 participants. The study started on 2011-05. Estimated completion is 2014-12.

What conditions does trial NCT01541644 study?

This clinical trial studies the following conditions: Multiple Myeloma, Peripheral Neuropathies.

What interventions are being tested in trial NCT01541644?

The interventions under investigation include: Acupuncture (DEVICE).

Who is sponsoring clinical trial NCT01541644?

This trial is sponsored by University of Maryland, Baltimore, which has 560 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01541644 being conducted?

This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Multiple Myeloma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT01541644's enrollment target sits among peer trials

27 364th of 438 higher than 75 of 438 other Multiple Myeloma trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Multiple Myeloma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00912041 · 27 participants · NA

    BrainGate2: Feasibility Study of an Intracortical Neural Interface System for Persons With Tetraplegia

  • NCT02847559 · 27 participants · Phase 2

    Optune Delivered Electric Field Therapy and Bevacizumab in Treating Patients With Recurrent or Progressive Grade 2 or 3 Meningioma

  • NCT03380195 · 27 participants · NA

    Effects of Watermelon Juice on Heart Rate Recovery and Post-exercise Muscle Soreness

  • NCT03384238 · 27 participants · Phase 1

    Panitumumab-IRDye800 in Patients With Pancreatic Cancer Undergoing Surgery

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01541644, the US trial registry maintained by the National Library of Medicine. NCT01541644 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.